Cargando…
Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
Patients with late‐stage Kellgren‐Lawrence knee osteoarthritis received a single intra‐articular injection of 1, 10, or 50 million bone marrow mesenchymal stromal cells (BM‐MSCs) in a phase I/IIa trial to assess safety and efficacy using a broad toolset of analytical methods. Besides safety, outcome...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646697/ https://www.ncbi.nlm.nih.gov/pubmed/30964245 http://dx.doi.org/10.1002/sctm.18-0183 |
_version_ | 1783437593893928960 |
---|---|
author | Chahal, Jaskarndip Gómez‐Aristizábal, Alejandro Shestopaloff, Konstantin Bhatt, Shashank Chaboureau, Amélie Fazio, Antonietta Chisholm, Jolene Weston, Amanda Chiovitti, Julia Keating, Armand Kapoor, Mohit Ogilvie‐Harris, Darrell J. Syed, Khalid A. Gandhi, Rajiv Mahomed, Nizar N. Marshall, Kenneth W. Sussman, Marshall S. Naraghi, Ali M. Viswanathan, Sowmya |
author_facet | Chahal, Jaskarndip Gómez‐Aristizábal, Alejandro Shestopaloff, Konstantin Bhatt, Shashank Chaboureau, Amélie Fazio, Antonietta Chisholm, Jolene Weston, Amanda Chiovitti, Julia Keating, Armand Kapoor, Mohit Ogilvie‐Harris, Darrell J. Syed, Khalid A. Gandhi, Rajiv Mahomed, Nizar N. Marshall, Kenneth W. Sussman, Marshall S. Naraghi, Ali M. Viswanathan, Sowmya |
author_sort | Chahal, Jaskarndip |
collection | PubMed |
description | Patients with late‐stage Kellgren‐Lawrence knee osteoarthritis received a single intra‐articular injection of 1, 10, or 50 million bone marrow mesenchymal stromal cells (BM‐MSCs) in a phase I/IIa trial to assess safety and efficacy using a broad toolset of analytical methods. Besides safety, outcomes included patient‐reported outcome measures (PROMs): Knee Injury and Osteoarthritis Outcome Score (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); contrast‐enhanced magnetic resonance imaging (MRI) for cartilage morphology (Whole Organ MRI Scores [WORMS]), collagen content (T2 scores), and synovitis; and inflammation and cartilage turnover biomarkers, all over 12 months. BM‐MSCs were characterized by a panel of anti‐inflammatory markers to predict clinical efficacy. There were no serious adverse events, although four patients had minor, transient adverse events. There were significant overall improvements in KOOS pain, symptoms, quality of life, and WOMAC stiffness relative to baseline; the 50 million dose achieved clinically relevant improvements across most PROMs. WORMS and T2 scores did not change relative to baseline. However, cartilage catabolic biomarkers and MRI synovitis were significantly lower at higher doses. Pro‐inflammatory monocytes/macrophages and interleukin 12 levels decreased in the synovial fluid after MSC injection. The panel of BM‐MSC anti‐inflammatory markers was strongly predictive of PROMs over 12 months. Autologous BM‐MSCs are safe and result in significant improvements in PROMs at 12 months. Our analytical tools provide important insights into BM‐MSC dosing and BM‐MSC reduction of synovial inflammation and cartilage degradation and provide a highly predictive donor selection criterion that will be critical in translating MSC therapy for osteoarthritis. stem cells translational medicine 2019;8:746&757 |
format | Online Article Text |
id | pubmed-6646697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66466972019-07-31 Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation Chahal, Jaskarndip Gómez‐Aristizábal, Alejandro Shestopaloff, Konstantin Bhatt, Shashank Chaboureau, Amélie Fazio, Antonietta Chisholm, Jolene Weston, Amanda Chiovitti, Julia Keating, Armand Kapoor, Mohit Ogilvie‐Harris, Darrell J. Syed, Khalid A. Gandhi, Rajiv Mahomed, Nizar N. Marshall, Kenneth W. Sussman, Marshall S. Naraghi, Ali M. Viswanathan, Sowmya Stem Cells Transl Med Human Clinical Article Patients with late‐stage Kellgren‐Lawrence knee osteoarthritis received a single intra‐articular injection of 1, 10, or 50 million bone marrow mesenchymal stromal cells (BM‐MSCs) in a phase I/IIa trial to assess safety and efficacy using a broad toolset of analytical methods. Besides safety, outcomes included patient‐reported outcome measures (PROMs): Knee Injury and Osteoarthritis Outcome Score (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); contrast‐enhanced magnetic resonance imaging (MRI) for cartilage morphology (Whole Organ MRI Scores [WORMS]), collagen content (T2 scores), and synovitis; and inflammation and cartilage turnover biomarkers, all over 12 months. BM‐MSCs were characterized by a panel of anti‐inflammatory markers to predict clinical efficacy. There were no serious adverse events, although four patients had minor, transient adverse events. There were significant overall improvements in KOOS pain, symptoms, quality of life, and WOMAC stiffness relative to baseline; the 50 million dose achieved clinically relevant improvements across most PROMs. WORMS and T2 scores did not change relative to baseline. However, cartilage catabolic biomarkers and MRI synovitis were significantly lower at higher doses. Pro‐inflammatory monocytes/macrophages and interleukin 12 levels decreased in the synovial fluid after MSC injection. The panel of BM‐MSC anti‐inflammatory markers was strongly predictive of PROMs over 12 months. Autologous BM‐MSCs are safe and result in significant improvements in PROMs at 12 months. Our analytical tools provide important insights into BM‐MSC dosing and BM‐MSC reduction of synovial inflammation and cartilage degradation and provide a highly predictive donor selection criterion that will be critical in translating MSC therapy for osteoarthritis. stem cells translational medicine 2019;8:746&757 John Wiley & Sons, Inc. 2019-04-09 /pmc/articles/PMC6646697/ /pubmed/30964245 http://dx.doi.org/10.1002/sctm.18-0183 Text en © 2019 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Human Clinical Article Chahal, Jaskarndip Gómez‐Aristizábal, Alejandro Shestopaloff, Konstantin Bhatt, Shashank Chaboureau, Amélie Fazio, Antonietta Chisholm, Jolene Weston, Amanda Chiovitti, Julia Keating, Armand Kapoor, Mohit Ogilvie‐Harris, Darrell J. Syed, Khalid A. Gandhi, Rajiv Mahomed, Nizar N. Marshall, Kenneth W. Sussman, Marshall S. Naraghi, Ali M. Viswanathan, Sowmya Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation |
title | Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation |
title_full | Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation |
title_fullStr | Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation |
title_full_unstemmed | Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation |
title_short | Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation |
title_sort | bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation |
topic | Human Clinical Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646697/ https://www.ncbi.nlm.nih.gov/pubmed/30964245 http://dx.doi.org/10.1002/sctm.18-0183 |
work_keys_str_mv | AT chahaljaskarndip bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT gomezaristizabalalejandro bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT shestopaloffkonstantin bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT bhattshashank bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT chaboureauamelie bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT fazioantonietta bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT chisholmjolene bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT westonamanda bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT chiovittijulia bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT keatingarmand bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT kapoormohit bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT ogilvieharrisdarrellj bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT syedkhalida bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT gandhirajiv bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT mahomednizarn bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT marshallkennethw bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT sussmanmarshalls bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT naraghialim bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation AT viswanathansowmya bonemarrowmesenchymalstromalcelltreatmentinpatientswithosteoarthritisresultsinoverallimprovementinpainandsymptomsandreducessynovialinflammation |